admin

It’s good to have friends in high places. Especially friends who can leverage more than 30 years of experience in technology and business to nurture and foster your startup seed.

1776, a new startup incubator based in Washington, D.C., just announced a brand-new partnership with Microsoft, in which leaders from the company will collaborate with startups to guide them from a technical and business standpoint.

“[Microsoft] will help startups to leverage platforms upon which they can build innovative apps with the ability to scale rapidly and efficiently,” says 1776 co-founder Donna Harris. “Through 1776, they’re also providing mentorships for architects who can ensure that startups are maximizing the potential of these tools and platforms.”

Notice of Change to Earliest Start Date for Applications Submitted to RFA-DA-14-002 “Short-term Mentored Career Enhancement Awards in the Basic Behavioral and Social Sciences: Cross-Training at the Intersection of Animal Models and Human Investigation (K18)”

On June 26, 2013, United Therapeutics Corporation (the “Company”) held its 2013 annual meeting of shareholders. The Company’s shareholders considered three matters, each of which is described in more detail in the Company’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 30, 2013. The final voting results for the meeting are as follows:

1. The Company’s shareholders elected the following nominees as Class II directors, to serve three-year terms until the 2016 annual meeting of shareholders or until their successors are duly elected and qualified or their office is otherwise vacated, by the votes set forth below:

Sources inform “Globes” that AstraZeneca plc (NYSE; LSE; OMX: AZN) has teamed with Israeli real estate company Minrav Holdings Ltd. (TASE: MNRV) to bid in the Office of the Chief Scientist’s biotechnology incubator tender. AstraZeneca will handle the consortium’s professional side, and Minrav will be responsible for financing.

The AstraZeneca-Minrav consortium is bidding against a consortium of OrbiMed Israel and the venture capital arms of Johnson & Johnson (NYSE: JNJ) and Japan’s Takeda Pharmaceuticals Co. Ltd. (TSE: 4502).

New Enterprise Associates has increased its focus on companies developing drugs for rare disease, an effort that’s paying off. Portfolio company Prosensa Holding BV, which it backed last year, has just gone public on Nasdaq. The company develops therapies for rare conditions such as Duchenne muscular dystrophy, myotonic dystrophy and Huntington’s disease. 

Johns Hopkins Montgomery County has received the 2013 Visionary Award from the Montgomery County Chamber of Commerce.

Before an audience of hundreds at the Chamber’s Annual Awards Dinner, Campus Executive Elaine Amir thanked the Chamber for the recognition, thanked Montgomery County for having the foresight to establish the campus in 1985 and applauded County Executive Ike Leggett for his encouragement and support.